Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.
2.
3.

Counting and discounting gained life-years.

Søgaard J, Gyrd-Hansen D.

Dev Health Econ Public Policy. 1998;6:51-74.

PMID:
10662409
4.

Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children.

Gutiérrez de Mesa E, Hidalgo I, Christidis P, Ciscar JC, Vegas E, Ibarreta D.

Mol Diagn Ther. 2007;11(5):313-23.

PMID:
17963419
5.

Discounting health effects in pharmacoeconomic evaluations: current controversies.

Bos JM, Postma MJ, Annemans L.

Pharmacoeconomics. 2005;23(7):639-49.

PMID:
16173156
6.

Discounting in the economic evaluation of health care interventions.

Krahn M, Gafni A.

Med Care. 1993 May;31(5):403-18. Review.

PMID:
8501989
7.

[Economic aspects of prevention].

König HH, Riedel-Heller S.

Internist (Berl). 2008 Feb;49(2):146-53. doi: 10.1007/s00108-007-1994-7. German.

PMID:
18210026
8.

Societal discounting of health effects in cost-effectiveness analyses: the influence of life expectancy.

Polinder S, Meerding WJ, van Exel J, Brouwer W.

Pharmacoeconomics. 2005;23(8):791-802.

PMID:
16097841
9.
10.

The value of prevention: economic aspects.

Jönsson B.

Ciba Found Symp. 1985;110:22-37.

PMID:
3921320
11.

Discounting life-years: whither time preference?

Gyrd-Hansen D, Søgaard J.

Health Econ. 1998 Mar;7(2):121-7. Review.

PMID:
9565168
13.
14.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

15.

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.

Lamotte M, Annemans L, Evers T, Kubin M.

Pharmacoeconomics. 2006;24(2):155-69.

PMID:
16460136
16.

Cost-effectiveness of a community-level HIV risk reduction intervention for women living in low-income housing developments.

Johnson-Masotti AP, Pinkerton SD, Sikkema KJ, Kelly JA, Wagstaff DA.

J Prim Prev. 2005 Jul;26(4):345-62.

PMID:
15995803
17.
18.

Discounting in cost-effectiveness analysis of healthcare programmes.

Katz DA, Welch HG.

Pharmacoeconomics. 1993 Apr;3(4):276-85.

PMID:
10146991
19.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

20.

Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model.

Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C.

Health Technol Assess. 2006 Nov;10(44):iii-iv, ix-x, 1-210. Review.

Supplemental Content

Support Center